Steven Robinette
Private Equity Investor at Atlas Venture Advisors, Inc.
Steven Robinette active positions
| Companies | Position | Start | End |
|---|---|---|---|
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 2015-08-31 | - |
Career history of Steven Robinette
Former positions of Steven Robinette
| Companies | Position | Start | End |
|---|---|---|---|
| VIGIL NEUROSCIENCE, INC. | Private Equity Investor | - | - |
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Private Equity Investor | - | - |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Private Equity Investor | - | - |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Private Equity Investor | - | - |
| KYMERA THERAPEUTICS, INC. | Private Equity Investor | - | - |
Training of Steven Robinette
| Imperial College London | Doctorate Degree |
| University of Florida | Undergraduate Degree |
Statistics
International
| United States | 8 |
| United Kingdom | 2 |
Operational
| Private Equity Investor | 6 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Health Technology |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Steven Robinette
- Experience
